Sutro Biopharma (STRO)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Sutro Biopharma.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 9 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 24.20 $ — 58% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 97.3% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 10
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -7.80 | -8.31 – -7.30 | 45 | 51.8% | 2 |
| 12/31/2027 | -6.89 | -10.31 – -4.86 | 32 | 11.8% | 4 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -2.09 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -4.37 | -333.20 | 15 | -87.00 | -489.20 | -72 | -73 |
| 2025: Q1 | -4.58 | – | 17 | 33.80 | -436.60 | -68 | -69 |
| 2025: Q2 | -0.69 | – | 64 | 148.00 | -18.00 | -45 | -45 |
| 2025: Q3 | -3.43 | – | 10 | 13.80 | -586.60 | -38 | -38 |
| 2025: Q4 | -2.82 | – | 12 | -21.40 | -401.50 | -26 | -27 |
| 2026: Q1 | -2.32 | – | 15 | -16.50 | -265.00 | -42 | -42 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 60 | 1 | 2 | 38.58 | -13 | -91 | 69 |
| 2017 | 52 | -19 | -20 | -2.81 | -37 | -109 | 41 |
| 2018 | 38 | -37 | -35 | -15.45 | 13 | 132 | 223 |
| 2019 | 43 | -55 | -56 | -24.28 | -65 | 98 | 156 |
| 2020 | 43 | -71 | -32 | -0.99 | -68 | 332 | 394 |
| 2021 | 62 | -99 | -106 | -22.88 | -82 | 253 | 341 |
| 2022 | 68 | -129 | -119 | -23.49 | 4 | 217 | 407 |
| 2023 | 154 | -89 | -107 | -17.75 | -112 | 150 | 471 |
| 2024 | 62 | -238 | -227 | -29.61 | -192 | 45 | 387 |
| 2025 | 102 | -105 | -191 | -22.49 | -177 | -132 | 174 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Sutro Biopharma, Inc. ist ein onkologisches Unternehmen.
| Employees | 133 |
|---|---|
| Headquarters | South San Francisco, CA |
| Address | 111 Oyster Point Boulevard, 94080 South San Francisco, United States |
| Phone | 650 881 6500 |
| Website | sutrobio.com |
| IPO Date | 27. Sep 2018 |
| ISIN | US8693671021 |
| Stock Split | 1:10 on 12/03/2025 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Jane Chung R.Ph. | CEO & Director | 1971 |
| Gregory K. Chow BA, CPA, MBA | Chief Financial Officer | 1973 |
| Hans-Peter Gerber Ph.D. | Chief Scientific Officer | 1964 |
| James R. Swartz DSc, Ph.D., Sc.D. | Founder | – |
| Devendra Luhar | Senior Vice President of Technical Operations | – |
| David Pauling J.D., M.A. | Chief Administrative Officer & General Counsel | 1974 |
| Kari E. Leetch | Senior VP and Head of People & Culture | – |
| Jonathan Fawcett DPHIL, MBBS | VP & Head of Clinical Development | – |
| Regina Cheng | Vice President & Controller | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.